Skip to main content

Table 1 Clinical characteristics of the men diagnosed with prostate cancer (PrCa) in the full cohort and in the genotyped subcohort.

From: Serum levels of selenium and smoking habits at age 50 influence long term prostate cancer risk; a 34 year ULSAM follow-up

  PrCa in full cohort (n = 208) PrCa in subcohort (n = 126)
Age at diagnosis: median (range) 73 (57-83.0) 75 (59-82.0)
Diagnosis confirmed by: n (%)     
Histology 164 (78.8) 112 (88.9)
Cytology 33 (15.9) 11 (8.7)
Clinical examination only 3 (1.4) 1 (0.8)
Information missing 8 (3.8) 2 (1.6)
Diagnosis suspected from: n(%)     
PSA Screening 2 (1.0) 2 (1.6)
LUTS** 127 (61.1) 85 (67.5)
Other urological or skeletal symptoms 33 (15.9) 18 (14.3)
Incidentally discovered† 15 (7.2) 10 (7.9)
Other 7 (3.4) 6 (4.8)
Information missing 24 (11.5) 5 (4.0)
PSA-level***, ng/mL n (%)     
≤4 8 (3.8) 6 (4.8)
4.1-10 24 (11.5) 18 (14.3)
10.1-20 31 (14.9) 25 (19.8)
20.1-100 41 (19.7) 33 (26.2)
> 100 23 (11.1) 14 (11.1)
Information missing 81 (38.9) 30 (23.8)
T-stage‡, n (%)     
T0/T1ab 28 (13.5) 20 (15.9)
T1c 25 (12.0) 19 (15.1)
T2 89 (42.8) 55 (43.7)
T3-4 47 (22.6) 27 (21.4)
TX/Information Missing 19 (9.1) 5 (4.0)
N-stage‡, n (%)     
N0 32 (15.4) 22 (17.5)
N1 12 (5.8) 5 (4.0)
NX 142 (68.3) 90 (71.4)
Information missing 22 (10.6) 9 (7.1)
M-stage‡in combination with PSA, n (%)     
M0 88 (42.3) 61 (48.4)
MX, PSA ≤20 11 (5.3) 11 (8.7)
MX, 20 < PSA≤100 26 (12.5) 17 (13.5)
M1/PSA > 100 48 (23.1) 22 (17.5)
Information missing 35 (16.8) 15 (11.9)
Gleason score*, n(%)     
2-6 50 (41.3) 41 (45.6)
7 20 (16.5) 17 (18.9)
8-10 31 (25.6) 26 (28.9)
Information missing 20 (16.5) 6 (6.7)
  1. *WHO grade translated into Gleason score G1 = 2-6, G2 = 7, G3 = 8-10 in 42 cases
  2. ** Lower urinary tract symptoms.
  3. *** Prostate specific antigen
  4. †Incidentally discovered under investigation for symptoms not related to the urinary tract
  5. ‡As classified by the International Union Against Cancer (UICC)